Shiri Klein
Jerusalem, JM, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy.
Journal: Frontiers in immunology
Published: September 02, 2024
The future of affordable cancer immunotherapy.
Journal: Frontiers in immunology
Published: June 27, 2023
The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.
Journal: Immunologic research
Published: February 28, 2022
Single-cell transcriptomics reveals a senescence-associated IL-6/CCR6 axis driving radiodermatitis.
Journal: EMBO molecular medicine
Published: December 29, 2021
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.
Journal: Cancer immunology research
Published: September 21, 2020
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study.
Journal: Frontiers in oncology
Published: November 05, 2019
Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Journal: Cytokine
Published: October 06, 2017
CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.
Journal: Cancer research
Published: February 13, 2017
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 22, 2016
The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 01, 2015
Last Updated: 09/26/2026